Law360 | Mike LaSusa The U.S. federal government filed an amicus brief Friday at the Ninth Circuit backing arguments made by Bayer AG, which is seeking to overturn a $25 million verdict in favor of a man who claims the weedkiller Roundup caused his cancer. The government’s 33-page filing supported Bayer’s contention that the Federal […]
Wall Street Journal | By Jacob Bunge and Timothy Puko The Trump administration is backing Bayer AG in the German chemical maker’s high-stakes court fight over the world’s most widely used weedkiller. The Environmental Protection Agency, working with the Justice Department, filed court papers Friday supporting Bayer’s argument that glyphosate, the active ingredient in the […]
Law.com | By Amanda Bronstad
Monsanto Co. has asked a federal appeals court to reverse a verdict over its herbicide Roundup that it said “defies both expert regulatory judgment and sound science.”
Reuters | By Tina Bellon
Bayer AG on Monday said it has asked a U.S. federal appeals court to throw out a $25 million judgment it was ordered to pay to a California man who blamed the company’s Roundup weed killer for his cancer.
The New York Times | By Reuters – Panarat Thepgumpanat and Panu Wongcha-um
Many local farmers groups have been staging protests opposing the ban, saying that the lack of inexpensive substitutes would harm their livelihood.
The Wall Street Journal | By Sara Randazzo and Jacob Bunge
Lawyers have clamored to sign up Roundup plaintiffs, making it the top product targeted by mass-tort lawyers and marketing companies in recent years, according to X Ante, which sells data to companies on mass-tort advertising.
Slate | By Ted Williams
All scientific bodies that have seriously studied glyphosate report no link to cancer.
The New York Times | By Patricia Cohen
Glyphosate is already the most widely used agricultural chemical in history, and farmers will continue to depend on Roundup, investors reason, especially as a growing population increases the demand for food.
The Recorder | By Amanda Bronstad
A California jury that awarded a $289 million Roundup verdict disregarded science and the consensus of federal regulators and fell victim to “emotional manipulation,” according to the state’s doctors, farmers and biotech firm Genentech Inc., in amicus briefs filed in Monsanto’s appeal.
Northern California Record | By Rich Peters
Four amicus briefs have been filed in the California Court of Appeals in the case of Dewayne Johnson v. Monsanto raising “concerns about the methods used to determine medical causation and the award of punitive damages in the Johnson case, as well as the reliance of businesses and consumers on regulatory approvals,” said a media representative for Bayer.
Bayer today provided an update on its five-point plan to address future Roundup™ litigation risk after its May 27th decision to withdraw from the national class process. The company is now in more control of important aspects of the risk mitigation process and has sketched out two basic scenarios going forward to provide a path to closure of this litigation. The first scenario is based on obtaining a favorable decision by the United States Supreme Court on a cross-cutting issue like federal preemption which would effectively and largely end the U.S. Roundup™ litigation. The second scenario assumes that the Supreme Court either declines to hear the Hardeman case or issues a ruling in favor of plaintiff – in that case the company would activate its own claims administration program.
Read about the five-point plan here.